Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
KRAS wild-type pancreatic ductal adenocarcinoma
Data

Cancers·KRAS wild-type pancreatic ductal adenocarcinoma

DataKRAS wild-type pancreatic ductal adenocarcinoma

Back to the KRAS wild-type pancreatic ductal adenocarcinoma hub →73 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Data

Related pages

73

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

Cancer
Borderline resectable pancreatic ductal adenocarcinoma
Shares NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV), Eileen M. O'Reilly, Pancreatic cancer (KEGG map), KRAS G12C-mutant pancreatic ductal adenocarcinoma and the tags subtype-page, gastrointestinal.
Cancer
Advanced and metastatic small bowel adenocarcinoma
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), HER2, KRAS, Comprehensive genomic profiling and the tags subtype-page, gastrointestinal.
Cancer
Localised small bowel adenocarcinoma (stage I to III, resected)
Shares Ampullary cancer (ampulla of Vater), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), HER2, KRAS and the tags subtype-page, gastrointestinal.
Cancer
Resectable pancreatic ductal adenocarcinoma
Shares Classical versus basal-like (squamous) subtypes of pancreatic cancer, and GATA6, Eileen M. O'Reilly, Pancreatic acinar cell carcinoma, Pancreatic cancer (KEGG map) and the tags subtype-page, gastrointestinal.
Cancer
Pancreatoblastoma
Shares Pancreatic acinar cell carcinoma, Pancreatic cancer (KEGG map), KRAS, Pancreatic ductal adenocarcinoma and the tags subtype-page, gastrointestinal.
Cancer
Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), KRAS, Pembrolizumab, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Metastatic and recurrent anal squamous cell carcinoma
Shares Pembrolizumab, Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tags subtype-page, gastrointestinal.
Cancer
Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei
Shares KRAS and the tags subtype-page, gastrointestinal.

technologies

Bispecific antibodies Comprehensive genomic profiling Cytotoxic chemotherapy Immune checkpoint inhibitors Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)Liquid biopsy (ctDNA)Platinum agents Small-molecule kinase inhibitors Topoisomerase-I inhibitors (and ADC payloads)

targets

ALK BRAF EGFR FGFR2 HER2 HER3 KRAS NTRK PD-1 ROS1

drugs

ApprovedSmall-molecule kinase inhibitors (BRAF + MEK)

Dabrafenib + trametinib · Tafinlar + Mekinist

ApprovedSmall-molecule TRK/ROS1/ALK TKI (CNS-penetrant)

Entrectinib · Rozlytrek

ApprovedCytotoxic regimen

FOLFIRINOX / mFOLFIRINOX

ApprovedNucleoside analogue (deoxycytidine)

Gemcitabine · Gemzar / Infugem

ApprovedCytotoxic regimen

Gemcitabine + nab-paclitaxel · Gemzar + Abraxane

ApprovedSmall-molecule pan-TRK inhibitor (first generation)

Larotrectinib · Vitrakvi

ApprovedCytotoxic regimen

NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) · Onivyde regimen

EstablishedHumanised anti-EGFR monoclonal antibody, intravenous

Nimotuzumab · BIOMAb EGFR / TheraCIM / CIMAher

ApprovedMonoclonal antibody (anti-PD-1)

Pembrolizumab · Keytruda / Keytruda Qlex (SC)

ApprovedSmall-molecule kinase inhibitor (ROS1 / NTRK)

Repotrectinib · Augtyro

ApprovedBispecific antibody (HER2×HER3)

Zenocutuzumab · Bizengri

companies

Bayer Biocon Bristol Myers Squibb CIMAB Eli Lilly (incl. Loxo)Eurofarma Ipsen Merck & Co. (MSD)Merus Novartis Pfizer (incl. Seagen)Roche / Genentech

pathways

Pancreatic cancer (KEGG map)RAS / RAF / MEK / ERK (MAPK)Receptor tyrosine kinase activation

terms

BRAF V600E mutation Classical versus basal-like (squamous) subtypes of pancreatic cancer, and GATA6 Driver mutation Drug resistance (primary and acquired)Gene fusion KRAS mutation subtypes (G12C, G12D, G12V)Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)

trials

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positi NOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

ideas

Automatic germline testing for every cancer type where it changes care

people

Anirban Maitra Eileen M. O'Reilly Eric Van Cutsem Lin Shen

key papers

eNRGy: efficacy of zenocutuzumab in NRG1 fusion-positive cancer Heining 2018: NRG1 fusions in KRAS wild-type pancreatic cancer Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma Integrated genomic characterization of pancreatic ductal adenocarcinoma Jones 2019: NRG1 gene fusions are recurrent, clinically actionable rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion

biomarkers

ALK fusion (ALK-positive)NTRK1/2/3 gene fusion

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-18. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

ProvenanceLast edited 2026-09-22 · Jude Gomila · Every pancreatic subtype page now rests on two to four la… · diff · file

Wikipedia

Pancreatic cancer

Sources & links

Wikipedia
NCCN Guidelines: Pancreatic Adenocarcinoma

subtype-page gastrointestinal

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of KRAS wild-type pancreatic ductal adenocarcinoma

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/kras-wild-type-pdac/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id kras-wild-type-pdac.

WebMCP tools registered on this page: onco_search, onco_get_entity.